Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis
| Autor: | Helmut W. Minne, C. E. Pepene, T Seck, Ingo J. Diel, Reinhard Ziegler, J Pfeilschifter |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Calcitonin
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Biopsy Osteoporosis In Vitro Techniques Iliac crest Bone remodeling Ilium Transforming Growth Factor beta1 Insulin-like growth factor Endocrinology Bone Density Insulin-Like Growth Factor II Transforming Growth Factor beta Internal medicine medicine Humans Insulin-Like Growth Factor I Growth Substances biology business.industry Estrogen Replacement Therapy Hormone replacement therapy (menopause) General Medicine Middle Aged medicine.disease medicine.anatomical_structure Insulin-like growth factor 2 biology.protein Alkaline phosphatase Sodium Fluoride Female business |
| Zdroj: | European journal of endocrinology. 150(1) |
| ISSN: | 0804-4643 |
| Popis: | OBJECTIVE: Data from cell culture experiments suggest that local growth factors (GFs) may mediate the effects of estrogens, calcitonin or fluor ions on the skeleton. To assess the in vivo relevance of the in vitro reports, the effect of fluor salts, hormone replacement therapy (HRT) and calcitonin on the concentrations of IGF-I, IGF-II and transforming growth factor (TGF)-beta 1 in bone matrix extracts from osteoporotic patients was evaluated. DESIGN: Iliac crest bone biopsies were obtained from 170 patients (76 men and 94 women) with primary osteoporosis aged 55.5+/-0.8 Years. METHODS: Bone matrix extraction was performed based on a guanidine-HCl/ethylendiamine-tetra-acetic acid method. RESULTS: In comparison with age- and body mass index (BMI)-matched controls, no influence of long-term therapy with fluor ions (n=41) or calcitonin (n=16) on the bone matrix concentration of GFs was noticed. Postmenopausal women with osteoporosis on HRT (n=39) had lower skeletal IGF-I but not IGF-II levels as compared with age- and BMI-matched non-users. However, the lower rate of bone turnover in women with HRT may account for this difference, since the significance was lost after adjustment for alkaline phosphatase. Likewise, a tendency for lower TGF-beta 1 levels was observed in HRT users as compared with non-users but was lost after adjustment for bone turnover. None of the therapies influenced the serum levels of GFs when patients receiving continuous therapy for at least 1 Year before bone biopsy were considered. CONCLUSIONS: Our data suggest no direct effect of fluor therapy on skeletal GFs levels. At the concentrations used, neither HRT nor calcitonin appeared to exert any significant influence on serum or bone matrix GF levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|